113 results on '"Kopp, Jeffrey B."'
Search Results
2. circMTND5 Participates in Renal Mitochondrial Injury and Fibrosis by Sponging MIR6812 in Lupus Nephritis.
- Author
-
Luan J, Jiao C, Ma C, Zhang Y, Hao X, Zhou G, Fu J, Qiu X, Li H, Yang W, Illei GG, Kopp JB, Pi J, and Zhou H
- Subjects
- Humans, Fibrosis, In Situ Hybridization, Fluorescence, Kidney pathology, Mitochondria metabolism, Kidney Diseases genetics, Kidney Diseases metabolism, Lupus Nephritis genetics, Lupus Nephritis metabolism, Lupus Nephritis pathology, MicroRNAs genetics, MicroRNAs metabolism, RNA, Circular genetics
- Abstract
Recent studies have focused on nuclear-encoded circular RNAs (circRNAs) in kidney diseases, but little is known about mitochondrial circRNAs. Differentially expressed circRNAs were analyzed by RNA deep sequencing from lupus nephritis (LN) biopsies and normal human kidneys. In LN renal biopsies, the most downregulated circRNA was circMTND5, which is encoded in the mitochondrial genome. We quantitated circMTND5 by qPCR and localized by fluorescence in situ hybridization (FISH). Mitochondrial abnormalities were identified by electron microscopy. The expression of mitochondrial genes was decreased, and the expression of profibrotic genes was increased on qPCR and immunostaining. RNA binding sites for MIR6812 and circMTND5 were predicted. MIR6812 expression was increased by FISH and qPCR. In HK-2 cells and its mitochondrial fraction, the role of circMTND5 sponging MIR6812 was assessed by their colocalization in mitochondria on FISH, RNA immunoprecipitation, and RNA pulldown coupled with luciferase reporter assay. circMTND5 knockdown upregulated MIR6812, decreased mitochondrial functional gene expression, and increased profibrotic gene expression. Overexpression of circMTND5 reversed these effects in hTGF- β stimulated HK-2 cells. Similar effects were observed in HK-2 cells with overexpression and with knockdown of MIR6812. We conclude that circMTND5 alleviates renal mitochondrial injury and kidney fibrosis by sponging MIR6812 in LN., Competing Interests: The authors have no relevant financial or nonfinancial interests to disclose., (Copyright © 2022 Junjun Luan et al.)
- Published
- 2022
- Full Text
- View/download PDF
3. LNA-anti-miR-150 alleviates renal interstitial fibrosis by reducing pro-inflammatory M1/M2 macrophage polarization.
- Author
-
Hao X, Luan J, Jiao C, Ma C, Feng Z, Zhu L, Zhang Y, Fu J, Lai E, Zhang B, Wang Y, Kopp JB, Pi J, and Zhou H
- Subjects
- Animals, Antagomirs pharmacology, Cytokines metabolism, Fibrosis, Folic Acid pharmacology, Humans, Macrophages metabolism, Mice, Suppressor of Cytokine Signaling Proteins metabolism, Kidney Diseases pathology, MicroRNAs metabolism
- Abstract
Renal interstitial fibrosis (RIF) is a common pathological feature contributing to chronic injury and maladaptive repair following acute kidney injury. Currently, there is no effective therapy for RIF. We have reported that locked nuclear acid (LNA)-anti-miR-150 antagonizes pro-fibrotic pathways in human renal tubular cells by regulating the suppressor of cytokine signal 1 (SOCS1)/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. In the present study, we aimed to clarify whether LNA-anti-miR-150 attenuates folic acid-induced RIF mice by regulating this pathway and by reducing pro-inflammatory M1/M2 macrophage polarization. We found that renal miR-150 was upregulated in folic acid-induced RIF mice at day 30 after injection. LNA-anti-miR-150 alleviated the degree of RIF, as shown by periodic acid-Schiff and Masson staining and by the expression of pro-fibrotic proteins, including alpha-smooth muscle actin and fibronectin. In RIF mice, SOCS1 was downregulated, and p-JAK1 and p-STAT1 were upregulated. LNA-anti-miR-150 reversed the changes in renal SOCS1, p-JAK1, and p-STAT1 expression. In addition, renal infiltration of total macrophages, pro-inflammatory M1 and M2 macrophages as well as their secreted cytokines were increased in RIF mice compared to control mice. Importantly, in folic acid-induced RIF mice, LNA-anti-miR-150 attenuated the renal infiltration of total macrophages and pro-inflammatory subsets, including M1 macrophages expressing CD11c and M2 macrophages expressing CD206. We conclude that the anti-renal fibrotic role of LNA-anti-miR-150 in folic acid-induced RIF mice may be mediated by reducing pro-inflammatory M1 and M2 macrophage polarization via the SOCS1/JAK1/STAT1 pathway., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Hao, Luan, Jiao, Ma, Feng, Zhu, Zhang, Fu, Lai, Zhang, Wang, Kopp, Pi and Zhou.)
- Published
- 2022
- Full Text
- View/download PDF
4. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
- Author
-
Yang YW, Poudel B, Frederick J, Dhillon P, Shrestha R, Ma Z, Wu J, Okamoto K, Kopp JB, Booten SL, Gattis D, Watt AT, Palmer M, Aghajan M, and Susztak K
- Subjects
- Animals, Apolipoprotein L1 genetics, Apolipoproteins genetics, Genetic Variation, Mice, Mice, Transgenic, Oligonucleotides, Antisense genetics, Kidney Diseases genetics, Kidney Diseases therapy, Podocytes, Renal Insufficiency
- Abstract
Coding variants (named G1 and G2) in Apolipoprotein L1 (APOL1) can explain most excess risk of kidney disease observed in African American individuals. It has been proposed that risk variant APOL1 dose, such as increased risk variant APOL1 level serves as a trigger (second hit) for disease development. The goal of this study was to determine whether lowering risk variant APOL1 levels protects from disease development in a podocyte-specific transgenic mouse disease model. We administered antisense oligonucleotides (ASO) targeting APOL1 to podocyte-specific G2APOL1 mice and observed efficient reduction of APOL1 levels. APOL1 ASO1, which more efficiently lowered APOL1 transcript levels, protected mice from albuminuria, glomerulosclerosis, tubulointerstitial fibrosis, and renal failure. Administration of APOL1 ASO1 was effective even for established disease in the NEFTA-rtTA/TRE-G2APOL1 (NEFTA/G2APOL1) mice. We observed a strong correlation between APOL1 transcript level and disease severity. We concluded that APOL1 ASO1 may be an effective therapeutic approach for APOL1-associated glomerular disease., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The American Society of Gene and Cell Therapy. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
5. Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design.
- Author
-
Wester CW, Shepherd BE, Wudil UJ, Musa BM, Ingles DJ, Prigmore HL, Dankishiya FS, Ahonkhai AA, Grema BA, Budge PJ, Takakura A, Olabisi OA, Winkler CA, Kopp JB, Bonventre JV, Wyatt CM, and Aliyu MH
- Subjects
- Adult, Albuminuria epidemiology, Albuminuria etiology, Apolipoprotein L1, Humans, Nigeria epidemiology, Coinfection, Diabetes Mellitus, Type 2, HIV Infections complications, HIV Infections drug therapy, Hypertension complications, Hypertension epidemiology, Kidney Diseases, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
Background: Microalbuminuria is an independent risk factor for cardiovascular and kidney disease and a predictor of end organ damage, both in the general population and in persons with HIV (PWH). Microalbuminuria is also an important risk factor for mortality in PWH treated with antiretroviral therapy (ART). In the ongoing Renal Risk Reduction (R3) study in Nigeria, we identified a high prevalence of microalbuminuria confirmed by two measurements 4-8 weeks apart in ART-experienced, virologically suppressed PWH. Although Stage 1 or 2 hypertension and exposure to potentially nephrotoxic antiretroviral medications were common in R3 participants, other traditional risk factors for albuminuria and kidney disease, including diabetes, APOL1 high-risk genotype, and smoking were rare. Co-infection with endemic pathogens may also be significant contributors to albuminuria, but co-infections were not evaluated in the R3 study population., Methods: In Aim 1, we will cross-sectionally compare the prevalence of albuminuria and established kidney disease risk factors in a cohort of PWH to age- and sex-matched HIV-negative adults presenting for routine care at the Aminu Kano Teaching Hospital in Kano, Nigeria. We will leverage stored specimens from 2500 R3 participants and enroll an additional 500 PLWH recently initiated on ART (≤ 24 months) and 750 age- and sex-matched HIV-negative adults to determine the contribution of HIV, hypertension, and other comorbid medical conditions to prevalent albuminuria. In Aim 2, we will follow a cohort of 1000 HIV-positive, ART-treated and 500 HIV-negative normoalbuminuric adults for 30 months to evaluate the incidence and predictors of albuminuria., Discussion: The findings from this study will support the development of interventions to prevent or address microalbuminuria in PWH to reduce kidney and cardiovascular morbidity and mortality. Such interventions might include more intensive monitoring and treatment of traditional risk factors, the provision of renin-angiotensin aldosterone system or sodium-glucose cotransporter-2 inhibitors, consideration of changes in ART regimen, and screening and treatment for relevant co-infections., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
6. Impact of APOL1 kidney risk variants on glomerular transcriptomes.
- Author
-
Kopp JB and Heymann J
- Subjects
- Humans, Kidney metabolism, Lipoproteins, HDL genetics, Risk Factors, Apolipoprotein L1 genetics, Kidney Diseases genetics, Kidney Diseases metabolism, Transcriptome
- Abstract
McNulty and colleagues describe the glomerular transcriptional landscape of subjects with APOL1 (the gene encoding apolipoprotein L1)-associated kidney disease, using bulk RNA sequencing. They found the following: APOL1 gene expression was higher in individuals with APOL1 high-risk genetic status; in glomeruli, STC1, encoding stanniocalcin, was the most upregulated gene, and CCL18, encoding C-C motif chemokine ligand 18, was the most downregulated gene; and nuclear factor kappa BNF-κB inhibitor-interacting Ras-like 1 (NKIRAS1) is the strongest hub gene. These findings identify disease pathways that might mediate or mitigate APOL1-associated nephropathies., (Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
7. Emerging Role of Circular RNAs in Kidney Diseases in Nephrology.
- Author
-
Ma C, Luan J, Kopp JB, and Zhou H
- Subjects
- Humans, Kidney, RNA, Circular genetics, Kidney Diseases genetics, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic genetics, Lupus Nephritis genetics, Nephrology
- Abstract
Background: Circular RNAs (circRNAs) have been identified to be involved in a variety of human diseases such as cancers, cardiovascular diseases, and autoimmune diseases. In recent years, the role of circRNAs in the development of kidney diseases in nephrology has been gradually recognized., Objective: We updated and described the current status of circRNAs in kidney diseases in nephrology. We particularly focused on the roles and mechanisms of circRNAs in systemic lupus erythematosus and lupus nephritis., Methods: We summarized recent reports published on PubMed, Web of Science, Scopus, Scielo databases using keywords circRNAs, kidney diseases or renal diseases, or systemic lupus erythematosus., Results: Studies of circRNAs in certain kidney diseases, such as acute kidney injury, focal segmental glomerulosclerosis, idiopathic membranous nephropathy, IgA nephropathy, diabetic nephropathy, hypertensive renal damage, and particular lupus nephritis address the function and pathogenesis of circRNAs. Mechanisms of circRNAs in the above human kidney diseases so far have focused on the role of sponging microRNAs and regulating the expression of target genes. Moreover, circRNAs have been detected in blood, urine, and kidney tissue samples. These results suggest that circRNAs can serve as biomarkers for the diagnosis and monitoring of the progression of kidney diseases., Conclusion: CircRNAs play important roles in the pathogenesis, diagnosis, and treatment of kidney diseases emphasizing lupus nephritis in nephrology., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2022
- Full Text
- View/download PDF
8. The key role of NLRP3 and STING in APOL1-associated podocytopathy.
- Author
-
Wu J, Raman A, Coffey NJ, Sheng X, Wahba J, Seasock MJ, Ma Z, Beckerman P, Laczkó D, Palmer MB, Kopp JB, Kuo JJ, Pullen SS, Boustany-Kari CM, Linkermann A, and Susztak K
- Subjects
- Animals, Apolipoprotein L1 physiology, Humans, Mice, Apolipoprotein L1 genetics, Kidney Diseases etiology, Membrane Proteins physiology, NLR Family, Pyrin Domain-Containing 3 Protein physiology, Podocytes pathology
- Abstract
Coding variants in apolipoprotein L1 (APOL1), termed G1 and G2, can explain most excess kidney disease risk in African Americans; however, the molecular pathways of APOL1-induced kidney dysfunction remain poorly understood. Here, we report that expression of G2 APOL1 in the podocytes of Nphs1rtTA/TRE-G2APOL1 (G2APOL1) mice leads to early activation of the cytosolic nucleotide sensor, stimulator of interferon genes (STING), and the NLR family pyrin domain-containing 3 (NLRP3) inflammasome. STING and NLRP3 expression was increased in podocytes from patients with high-risk APOL1 genotypes, and expression of APOL1 correlated with caspase-1 and gasdermin D (GSDMD) levels. To demonstrate the role of NLRP3 and STING in APOL1-associated kidney disease, we generated transgenic mice with the G2 APOL1 risk variant and genetic deletion of Nlrp3 (G2APOL1/Nlrp3 KO), Gsdmd (G2APOL1/Gsdmd KO), and STING (G2APOL1/STING KO). Knockout mice displayed marked reduction in albuminuria, azotemia, and kidney fibrosis compared with G2APOL1 mice. To evaluate the therapeutic potential of targeting NLRP3, GSDMD, and STING, we treated mice with MCC950, disulfiram, and C176, potent and selective inhibitors of NLRP3, GSDMD, and STING, respectively. G2APOL1 mice treated with MCC950, disulfiram, and C176 showed lower albuminuria and improved kidney function even when inhibitor treatment was initiated after the development of albuminuria.
- Published
- 2021
- Full Text
- View/download PDF
9. Podocytopathy in Obesity: Challenges of Living Large.
- Author
-
Giannini G, Kopp JB, and Rosenberg AZ
- Subjects
- Humans, Kidney Glomerulus, Obesity complications, Insulin Resistance, Kidney Diseases, Podocytes
- Abstract
Renal injury resulting from obesity is a growing concern caused by the global obesity epidemic. We discuss the glomerular structure, obesity-related glomerular changes, and diagnostic pathologic criteria for obesity-related glomerulopathy. The three main hypothesized mechanisms of podocyte injury are mechanical stress on the podocytes, metabolic derangement, and genetic/molecular factors. Weight loss, renin-angiotensin-aldosterone system inhibitors, and improved insulin resistance may slow the progression. A more comprehensive understanding of obesity-related glomerulopathy will help in developing more effective therapies., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
10. APOL1 at 10 years: progress and next steps.
- Author
-
Freedman BI, Kopp JB, Sampson MG, and Susztak K
- Subjects
- Genetic Predisposition to Disease, Haplotypes, Humans, Kidney, Apolipoprotein L1 genetics, Kidney Diseases genetics, Kidney Diseases therapy
- Abstract
APOL1 kidney risk variants (RVs) were identified in 2010 as major drivers of glomerular, tubulointerstitial, and renal microvascular disease in individuals with sub-Saharan African ancestry. In December 2020, the "APOL1 at Ten" conference summarized the first decade of progress and discussed controversies and uncertainties that remain to be addressed. Topics included trypanosome infection and its role in the evolution of APOL1 kidney RVs, clinical phenotypes in APOL1-associated nephropathy, relationships between APOL1 RVs and background haplotypes on cell injury and molecular mechanisms initiating disease, the role of clinical APOL1 genotyping, and development of novel therapies for kidney disease. Future goals were defined, including improved characterization of various APOL1 RV phenotypes in patients and experimental preclinical models; further dissection of APOL1-mediated pathways to cellular injury and dysfunction in kidney (and other) cells; clarification of gene-gene and gene-environment interactions; and evaluation of the role for existing and novel therapies., (Copyright © 2021 International Society of Nephrology. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
11. Genetic Testing for APOL1 Genetic Variants in Clinical Practice: Finally Starting to Arrive.
- Author
-
Kopp JB and Winkler CA
- Subjects
- Black People genetics, Clinical Decision-Making, Genetic Predisposition to Disease, Glomerular Filtration Rate, Humans, Kidney physiopathology, Kidney Diseases diagnosis, Kidney Diseases ethnology, Kidney Diseases physiopathology, Phenotype, Predictive Value of Tests, Prognosis, Risk Assessment, Risk Factors, Apolipoprotein L1 genetics, Genetic Testing, Genetic Variation, Kidney Diseases genetics
- Published
- 2020
- Full Text
- View/download PDF
12. APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.
- Author
-
Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Gutiérrez OM, Irvin MR, Ix JH, Kopp JB, Kuller LH, Langefeld CD, Lipkowitz MS, Mukamal KJ, Musani SK, Naik RP, Pajewski NM, Peralta CA, Tin A, Wassel CL, Wilson JG, Winkler CA, Young BA, Zakai NA, and Freedman BI
- Subjects
- Cardiovascular Diseases etiology, Genetic Variation, Humans, Kidney Diseases complications, Risk Assessment, Black or African American genetics, Apolipoprotein L1 genetics, Cardiovascular Diseases genetics, Kidney Diseases genetics
- Abstract
Background: Two coding variants in the apo L1 gene ( APOL1 ) are strongly associated with kidney disease in blacks. Kidney disease itself increases the risk of cardiovascular disease, but whether these variants have an independent direct effect on the risk of cardiovascular disease is unclear. Previous studies have had inconsistent results., Methods: We conducted a two-stage individual participant data meta-analysis to assess the association of APOL1 kidney-risk variants with adjudicated cardiovascular disease events and death, independent of kidney measures. The analysis included 21,305 blacks from eight large cohorts., Results: Over 8.9±5.0 years of follow-up, 2076 incident cardiovascular disease events occurred in the 16,216 participants who did not have cardiovascular disease at study enrollment. In fully-adjusted analyses, individuals possessing two APOL1 kidney-risk variants had similar risk of incident cardiovascular disease (coronary heart disease, myocardial infarction, stroke and heart failure; hazard ratio 1.11, 95% confidence interval, 0.96 to 1.28) compared to individuals with zero or one kidney-risk variant. The risk of coronary heart disease, myocardial infarction, stroke and heart failure considered individually was also comparable by APOL1 genotype. APOL1 genotype was also not associated with death. There was no difference in adjusted associations by level of kidney function, age, diabetes status, or body-mass index., Conclusions: In this large, two-stage individual participant data meta-analysis, APOL1 kidney-risk variants were not associated with incident cardiovascular disease or death independent of kidney measures., (Copyright © 2019 by the American Society of Nephrology.)
- Published
- 2019
- Full Text
- View/download PDF
13. Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.
- Author
-
Aliyu MH, Wudil UJ, Ingles DJ, Shepherd BE, Gong W, Musa BM, Muhammad H, Sani MU, Abdu A, Nalado AM, Atanda A, Ahonkhai AA, Ikizler TA, Winkler CA, Kopp JB, Kimmel PL, and Wester CW
- Subjects
- Adolescent, Adult, Aged, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Clinical Protocols, HIV Infections complications, Humans, Kidney Diseases genetics, Medication Adherence, Middle Aged, Sample Size, Young Adult, Apolipoprotein L1 genetics, HIV Infections drug therapy, Kidney Diseases etiology, Research Design
- Abstract
Background: Individuals with two copies of the apolipoprotein-1 (APOL1) gene risk variants are at high risk (HR) for non-diabetic kidney disease. The presence of these risk variants is highest in West Africa, specifically in Nigeria. However, there is limited availability of dialysis and kidney transplantation in Nigeria, and most individuals will die soon after developing end-stage renal disease. Blocking the renin angiotensin aldosterone system with angiotensin-converting enzyme inhibitors (ACEi) is a well-recognized strategy to slow renal disease progression in patients with diabetes mellitus with chronic kidney disease (CKD) and in patients with HIV-associated nephropathy. We propose to determine whether presence of the APOL1 HR genotype alters or predicts responsiveness to conventional therapy to treat or prevent CKD and if addition of an ACEi to standard combination antiretroviral therapy (ART) reduces the risk of kidney complications among non-diabetic Nigerian adults., Methods/design: We will screen 2600 HIV-positive adults who have received ART to (1) determine the prevalence of APOL1 risk variants and assess whether APOL1 HR status correlates with prevalent albuminuria, estimated glomerular filtration rate (eGFR), and/or prevalent CKD; (2) assess, via a randomized, placebo-controlled trial (RCT) in a subset of these participants with microalbuminura (n = 280) whether addition of the ACEi, lisinopril, compared to standard of care, significantly reduces the incidence or progression of albuminuria; and (3) determine whether the APOL1 HR genotype is associated with worse kidney outcomes (i.e. eGFR slope or regression of albuminuria) among participants in the RCT., Conclusions: This study will examine the increasing prevalence of kidney diseases in HIV-positive adults in a West African population, and the relationship between these diseases and the APOL1 high-risk genotype. By evaluating the addition of an ACEi to the care of individuals with HIV infection who have albuminuria, our trial will provide definitive evidence to guide strategies for management and clinical care in this population, with the goal of reducing HIV-related kidney complications., Trial Registration: ClinicalTrials.gov, NCT03201939 . Registered on 26 August 2016.
- Published
- 2019
- Full Text
- View/download PDF
14. c-Src is in the effector pathway linking uPAR and podocyte injury.
- Author
-
Kopp JB and Heymann J
- Subjects
- Animals, Mice, Protein Isoforms, Receptors, Urokinase Plasminogen Activator, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Podocytes
- Abstract
The role of urokinase-type plasminogen activator receptor (uPAR) in kidney physiology and pathology has attracted considerable attention. The protein uPAR has dual functions: as a key regulator of plasmin generation and a component of the innate immune system. In the current issue, Wei and colleagues describe a transgenic mouse expressing Plaur RNA in glomerular podocytes. The mice manifested podocyte injury, including c-Src phosphorylation, proteinuria, and focal segmental glomerulosclerosis (FSGS). Plaur-transgenic mice on a β3 integrin-deficient background were protected from podocyte injury. Renal biopsies from subjects with FSGS, but not those with other glomerular diseases, manifested increased c-Src phosphorylation in podocytes. These findings suggest a novel injury mechanism in FSGS, with possible implications for new treatment strategies.
- Published
- 2019
- Full Text
- View/download PDF
15. Expanding the spectrum of APOL1-related renal disease: de novo collapsing glomerulopathy following kidney transplant.
- Author
-
Kopp JB
- Subjects
- Apolipoprotein L1, Genotype, Humans, Prognosis, Kidney Diseases, Kidney Transplantation
- Abstract
Santoriello et al. report a series of 38 cases of de novo collapsing glomerulopathy following kidney transplant. Associations included acute rejection, viral infection, and APOL1 high-risk genotype (the latter in 9 cases). Risk factors for collapsing glomerulopathy included acute rejection, viral infection, acute vaso-occlusive disease, and an African American donor. The data are suggestive of, but do not directly establish, a role for interferon in these associations., (Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
16. Apolipoprotein L1 nephropathies: 2017 in review.
- Author
-
Kopp JB, Roshanravan H, and Okamoto K
- Subjects
- Apolipoprotein L1 chemistry, Cardiovascular Diseases genetics, Gene Dosage, Genetic Variation, Humans, Kidney Diseases surgery, Kidney Transplantation, Mitochondria physiology, Risk Factors, Apolipoprotein L1 genetics, Apolipoprotein L1 metabolism, Kidney Diseases genetics, Kidney Diseases metabolism
- Abstract
Purpose of Review: To review publications relating to apolipoprotein L1 (APOL1) renal risk variants published 2017., Recent Findings: The study of APOL1 variants continues to be highly active; 24 articles published in 2017 were selected to highlight. These include clinical studies of kidney disease, kidney transplantation, hypertension, cardiovascular disease, and genetic diversity. Laboratory studies included APOL1 association with vesicle-associated membrane soluble N-ethylmaleimide-sensitive factor activating protein receptor protein and with soluble urokinase-type plasminogen activator receptor, mitochondrial dysfunction, endolysosomal dysfunction, and inflammasome activation., Summary: Our understanding of the role of APOL1 genetic variants and the mechanisms for renal toxicity continues to deepen. It is not yet clear which pathways are most relevant to human disease, and so, the most relevant drug targets remain to be defined.
- Published
- 2018
- Full Text
- View/download PDF
17. Kidney Diseases Associated with Human Immunodeficiency Virus Infection.
- Author
-
Cohen SD, Kopp JB, and Kimmel PL
- Subjects
- Humans, HIV Infections, Kidney Diseases
- Published
- 2018
- Full Text
- View/download PDF
18. APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.
- Author
-
Gutiérrez OM, Limou S, Lin F, Peralta CA, Kramer HJ, Carr JJ, Bibbins-Domingo K, Winkler CA, Lewis CE, and Kopp JB
- Subjects
- Adult, Age of Onset, Asymptomatic Diseases, Carotid Artery Diseases diagnostic imaging, Carotid Artery Diseases ethnology, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease ethnology, Female, Genetic Association Studies, Genetic Predisposition to Disease, Glomerular Filtration Rate, Humans, Hypertrophy, Left Ventricular diagnostic imaging, Hypertrophy, Left Ventricular ethnology, Incidence, Kidney physiopathology, Kidney Diseases diagnosis, Kidney Diseases ethnology, Kidney Diseases physiopathology, Male, Middle Aged, Phenotype, Prevalence, Prospective Studies, Risk Assessment, Risk Factors, United States epidemiology, Black or African American genetics, Apolipoprotein L1 genetics, Carotid Artery Diseases genetics, Coronary Artery Disease genetics, Genetic Variation, Hypertrophy, Left Ventricular genetics, Kidney Diseases genetics
- Abstract
Prior studies reported associations of APOL1 nephropathy risk variants with subclinical atherosclerosis. However, these findings were limited to older individuals with high comorbidities. To evaluate this in younger individuals, we calculated associations of APOL1 risk variants (high risk [2 risk variants] vs. low risk [0-1 risk variant]) with prevalent, incident, or progressive coronary artery calcification, a carotid intima media thickness over the 90th percentile, and left ventricular hypertrophy in 1315 black participants of the Coronary Artery Risk Development in Young Adults (CARDIA) study. The mean age of this cohort was 44.6 years and their mean estimated glomerular filtration rate was 102.5 ml/min/1.73m
2 . High-risk participants were found to be younger and have a higher prevalence of albuminuria than low-risk participants. In Poisson regression models adjusted for comorbidities and kidney function, the risk of prevalent coronary artery calcification (relative risk [95% confidence interval] 1.12 [0.72,1.71]), the incident coronary artery calcification (1.50 [0.87,2.59]), and the progression of coronary artery calcification (1.40 [0.88,2.23]) did not significantly differ in high vs. low-risk participants. Furthermore, the risk of carotid intima media thickness over the 90th percentile (1.28 [0.78,2.10]) and left ventricular hypertrophy (1.02[0.73,1.43]) did not significantly differ in high vs. low-risk participants in fully-adjusted models. Thus, APOL1 risk variants did not associate with subclinical markers of atherosclerosis or left ventricular hypertrophy in middle-aged black adults with preserved kidney function., (Copyright © 2017 International Society of Nephrology. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
19. SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
- Author
-
Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D'Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, and Levi M
- Subjects
- Animals, Diabetes Mellitus, Experimental, Diabetic Nephropathies prevention & control, Humans, Inflammation prevention & control, Mice, RNA, Messenger analysis, Sodium-Glucose Transporter 2 analysis, Sodium-Glucose Transporter 2 genetics, Diabetic Nephropathies metabolism, Kidney Diseases metabolism, Lipid Metabolism drug effects, Sodium-Glucose Transporter 2 Inhibitors
- Abstract
There is very limited human renal sodium gradient-dependent glucose transporter protein (SGLT2) mRNA and protein expression data reported in the literature. The first aim of this study was to determine SGLT2 mRNA and protein levels in human and animal models of diabetic nephropathy. We have found that the expression of SGLT2 mRNA and protein is increased in renal biopsies from human subjects with diabetic nephropathy. This is in contrast to db-db mice that had no changes in renal SGLT2 protein expression. Furthermore, the effect of SGLT2 inhibition on renal lipid content and inflammation is not known. The second aim of this study was to determine the potential mechanisms of beneficial effects of SGLT2 inhibition in the progression of diabetic renal disease. We treated db/db mice with a selective SGLT2 inhibitor JNJ 39933673. We found that SGLT2 inhibition caused marked decreases in systolic blood pressure, kidney weight/body weight ratio, urinary albumin, and urinary thiobarbituric acid-reacting substances. SGLT2 inhibition prevented renal lipid accumulation via inhibition of carbohydrate-responsive element-binding protein-β, pyruvate kinase L, SCD-1, and DGAT1, key transcriptional factors and enzymes that mediate fatty acid and triglyceride synthesis. SGLT2 inhibition also prevented inflammation via inhibition of CD68 macrophage accumulation and expression of p65, TLR4, MCP-1, and osteopontin. These effects were associated with reduced mesangial expansion, accumulation of the extracellular matrix proteins fibronectin and type IV collagen, and loss of podocyte markers WT1 and synaptopodin, as determined by immunofluorescence microscopy. In summary, our study showed that SGLT2 inhibition modulates renal lipid metabolism and inflammation and prevents the development of nephropathy in db/db mice., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
20. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.
- Author
-
Wang XX, Edelstein MH, Gafter U, Qiu L, Luo Y, Dobrinskikh E, Lucia S, Adorini L, D'Agati VD, Levi J, Rosenberg A, Kopp JB, Gius DR, Saleem MA, and Levi M
- Subjects
- Animals, Bile Acids and Salts, Humans, Hydrogen Peroxide, Male, Mice, Oxidative Stress, Podocytes, Signal Transduction, Superoxide Dismutase, Cholic Acids pharmacology, Cholic Acids therapeutic use, Diabetic Nephropathies etiology, Diabetic Nephropathies prevention & control, Kidney Diseases etiology, Kidney Diseases prevention & control, Obesity complications, Receptors, G-Protein-Coupled drug effects, Receptors, G-Protein-Coupled physiology
- Abstract
Obesity and diabetes mellitus are the leading causes of renal disease. In this study, we determined the regulation and role of the G protein-coupled bile acid receptor TGR5, previously shown to be regulated by high glucose and/or fatty acids, in obesity-related glomerulopathy (ORG) and diabetic nephropathy (DN). Treatment of diabetic db/db mice with the selective TGR5 agonist INT-777 decreased proteinuria, podocyte injury, mesangial expansion, fibrosis, and CD68 macrophage infiltration in the kidney. INT-777 also induced renal expression of master regulators of mitochondrial biogenesis, inhibitors of oxidative stress, and inducers of fatty acid β-oxidation, including sirtuin 1 (SIRT1), sirtuin 3 (SIRT3), and Nrf-1. Increased activity of SIRT3 was evidenced by normalization of the increased acetylation of mitochondrial superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) observed in untreated db/db mice. Accordingly, INT-777 decreased mitochondrial H2O2 generation and increased the activity of SOD2, which associated with decreased urinary levels of H2O2 and thiobarbituric acid reactive substances. Furthermore, INT-777 decreased renal lipid accumulation. INT-777 also prevented kidney disease in mice with diet-induced obesity. In human podocytes cultured with high glucose, INT-777 induced mitochondrial biogenesis, decreased oxidative stress, and increased fatty acid β-oxidation. Compared with normal kidney biopsy specimens, kidney specimens from patients with established ORG or DN expressed significantly less TGR5 mRNA, and levels inversely correlated with disease progression. Our results indicate that TGR5 activation induces mitochondrial biogenesis and prevents renal oxidative stress and lipid accumulation, establishing a role for TGR5 in inhibiting kidney disease in obesity and diabetes., (Copyright © 2016 by the American Society of Nephrology.)
- Published
- 2016
- Full Text
- View/download PDF
21. New horizons for human pathogenic autoantibodies.
- Author
-
Burbelo PD, Keller J, and Kopp JB
- Subjects
- Autoimmune Diseases pathology, Humans, Immunologic Deficiency Syndromes pathology, Kidney Diseases pathology, Lung Diseases pathology, Autoantibodies immunology, Autoimmune Diseases immunology, Immunologic Deficiency Syndromes immunology, Kidney Diseases immunology, Lung Diseases immunology
- Abstract
Pathogenic autoantibodies directed against secreted or membrane-associated autoantigens cause disease mainly by disrupting the function of target proteins or by promoting the destruction of cells expressing these cell-surface molecules. In the past decade, many new pathogenic autoantibodies have been identified in different autoimmune diseases. Here we describe several examples of autoimmune conditions caused by pathogenic autoantibodies against targets such as receptors, channels, and cell surface proteins in neurological diseases, glomerular proteins in kidney diseases, and various cytokines in pulmonary disease and acquired immunodeficiencies. The clinical features of these diseases, the structural and functional diversity of the target proteins, and methods used for autoantibody detection are discussed. Further study of pathogenic autoantibodies, particularly defining the full spectrum of target proteins, may uncover previously uncharacterized diseases, as well as generate new diagnostic and treatment options.
- Published
- 2015
22. APOL1 Kidney Disease Risk Variants: An Evolving Landscape.
- Author
-
Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, and Kopp JB
- Subjects
- Apolipoprotein L1, Apolipoproteins metabolism, Genotype, Humans, Kidney Diseases metabolism, Lipoproteins, HDL metabolism, Risk Factors, Apolipoproteins genetics, Genetic Predisposition to Disease, Kidney Diseases genetics, Lipoproteins, HDL genetics
- Abstract
Apolipoprotein L1 (APOL1) genetic variants account for much of the excess risk of chronic and end-stage kidney disease, which results in a significant global health disparity for persons of African ancestry. We estimate the lifetime risk of kidney disease in APOL1 dual-risk allele individuals to be at least 15%. Experimental evidence suggests a direct role of APOL1 in pore formation, cellular injury, and programmed cell death in renal injury. The APOL1 BH3 motif, often associated with cell death, is unlikely to play a role in APOL1-induced cytotoxicity because it is not conserved within the APOL family and is dispensable for cell death in vitro. We discuss two models for APOL1 trypanolytic activity: one involving lysosome permeabilization and another involving colloid-osmotic swelling of the cell body, as well as their relevance to human pathophysiology. Experimental evidence from human cell culture models suggests that both mechanisms may be operative. A systems biology approach whereby APOL1-associated perturbations in gene and protein expression in affected individuals are correlated with molecular pathways may be productive to elucidate APOL1 function in vivo., (Published by Elsevier Inc.)
- Published
- 2015
- Full Text
- View/download PDF
23. Copy Number Variation at the APOL1 Locus.
- Author
-
Ruchi R, Genovese G, Lee J, Charoonratana VT, Bernhardy AJ, Alper SL, Kopp JB, Thadhani R, Friedman DJ, and Pollak MR
- Subjects
- Black or African American, Apolipoprotein L1, Apolipoproteins L, Case-Control Studies, Gene Expression, Gene Frequency, Genes, Recessive, Genetic Loci, Genome, Human, Heterozygote, Human Genome Project, Humans, Kidney metabolism, Kidney pathology, Kidney Diseases diagnosis, Kidney Diseases ethnology, Kidney Diseases pathology, Molecular Motor Proteins genetics, Myosin Heavy Chains genetics, Pedigree, Risk, Apolipoproteins genetics, DNA Copy Number Variations, Gene Duplication, Genetic Predisposition to Disease, Kidney Diseases genetics, Lipoproteins, HDL genetics
- Abstract
Two coding variants in the APOL1 gene (G1 and G2) explain most of the high rate of kidney disease in African Americans. APOL1-associated kidney disease risk inheritance follows an autosomal recessive pattern: The relative risk of kidney disease associated with inheritance of two high-risk variants is 7-30 fold, depending on the specific kidney phenotype. We wished to determine if the variability in phenotype might in part reflect structural differences in APOL1 gene. We analyzed sequence coverage from 1000 Genomes Project Phase 3 samples as well as exome sequencing data from African American kidney disease cases for copy number variation. 8 samples sequenced in the 1000 Genomes Project showed increased coverage over a ~100kb region that includes APOL2, APOL1 and part of MYH9, suggesting the presence of APOL1 copy number greater than 2. We reasoned that such duplications should be enriched in apparent G1 heterozygotes with kidney disease. Using a PCR-based assay, we observed the presence of this duplication in additional samples from apparent G0G1 or G0G2 individuals. The frequency of this APOL1 duplication was compared among cases (n = 123) and controls (n = 255) with apparent G0G1 heterozygosity. The presence of APOL1 duplication was observed in 4.06% of cases and 0.78% controls, preliminary evidence that this APOL1 duplication may alter susceptibility to kidney disease (p = 0.03). Taqman-based copy number assays confirmed the presence of 3 APOL1 copies in individuals positive for this specific duplication by PCR assay, but also identified a small number of individuals with additional APOL1 copies of presumably different structure. These observations motivate further studies to better assess the contribution of APOL1 copy number on kidney disease risk and on APOL1 function. Investigators and clinicians genotyping APOL1 should also consider whether the particular genotyping platform used is subject to technical errors when more than two copies of APOL1 are present.
- Published
- 2015
- Full Text
- View/download PDF
24. JC viruria and kidney disease in APOL1 risk genotype individuals: is this a clue to a gene × environment interaction?
- Author
-
Kopp JB
- Subjects
- Apolipoprotein L1, Female, Humans, Male, Black or African American genetics, Apolipoproteins genetics, JC Virus isolation & purification, Kidney Diseases genetics, Kidney Diseases virology, Lipoproteins, HDL genetics, Polyomavirus Infections virology, Tumor Virus Infections virology
- Abstract
APOL1 nephropathy occurs in a minority of genetically at-risk individuals, suggesting that other factors, such as other genes or environmental factors, contribute. Divers and colleagues report that among individuals with two APOL1 risk alleles, those with JC viruria are less likely to manifest kidney disease compared with those lacking JC viruria. These data might suggest that JC virus infection confers protection against glomerular injury, perhaps by altering cell function or generating immunity against a related polyomavirus.
- Published
- 2013
- Full Text
- View/download PDF
25. The Gne M712T mouse as a model for human glomerulopathy.
- Author
-
Kakani S, Yardeni T, Poling J, Ciccone C, Niethamer T, Klootwijk ED, Manoli I, Darvish D, Hoogstraten-Miller S, Zerfas P, Tian E, Ten Hagen KG, Kopp JB, Gahl WA, and Huizing M
- Subjects
- Animals, Biomarkers metabolism, Carbohydrate Epimerases genetics, Carrier Proteins genetics, Dietary Supplements, Drug Evaluation, Preclinical methods, Hexosamines therapeutic use, Humans, Kidney Diseases drug therapy, Kidney Diseases metabolism, Kidney Diseases pathology, Kidney Glomerulus embryology, Kidney Glomerulus metabolism, Kidney Glomerulus ultrastructure, Membrane Proteins metabolism, Mice, Mice, Mutant Strains, Microscopy, Electron, Mutation, N-Acetylneuraminic Acid physiology, Podocytes metabolism, Podocytes ultrastructure, Real-Time Polymerase Chain Reaction methods, Sialoglycoproteins metabolism, Disease Models, Animal, Kidney Diseases genetics
- Abstract
Pathological glomerular hyposialylation has been implicated in certain unexplained glomerulopathies, including minimal change nephrosis, membranous glomerulonephritis, and IgA nephropathy. We studied our previously established mouse model carrying a homozygous mutation in the key enzyme of sialic acid biosynthesis, N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Mutant mice died before postnatal day 3 (P3) from severe glomerulopathy with podocyte effacement and segmental glomerular basement membrane splitting due to hyposialylation. Administration of the sialic acid precursor N-acetylmannosamine (ManNAc) led to improved sialylation and survival of mutant pups beyond P3. We determined the onset of the glomerulopathy in the embryonic stage. A lectin panel, distinguishing normally sialylated from hyposialylated glycans, used WGA, SNA, PNA, Jacalin, HPA, and VVA, indicating glomerular hyposialylation of predominantly O-linked glycoproteins in mutant mice. The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine model. ManNAc treatment appeared to ameliorate the hyposialylation status of mutant mice, indicated by a lectin histochemistry pattern similar to that of wild-type mice, with improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared with untreated mutant mice. These findings suggest application of our lectin panel for categorizing human kidney specimens based on glomerular sialylation status. Moreover, the partial restoration of glomerular architecture in ManNAc-treated mice highlights ManNAc as a potential treatment for humans affected with disorders of glomerular hyposialylation., (Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
26. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
- Author
-
Zhang Y, Conti MA, Malide D, Dong F, Wang A, Shmist YA, Liu C, Zerfas P, Daniels MP, Chan CC, Kozin E, Kachar B, Kelley MJ, Kopp JB, and Adelstein RS
- Subjects
- Animals, Cataract metabolism, Cataract pathology, Female, Fluorescent Antibody Technique, Genes, Lethal, Hearing Loss metabolism, Hearing Loss pathology, Heterozygote, Homozygote, Humans, Immunoblotting, Kidney Diseases metabolism, Kidney Diseases pathology, Male, Megakaryocytes metabolism, Mice, Mice, Transgenic, Myosin Heavy Chains, Platelet Count, Thrombocytopenia metabolism, Thrombocytopenia pathology, Cataract etiology, Disease Models, Animal, Hearing Loss etiology, Kidney Diseases etiology, Megakaryocytes pathology, Mutation genetics, Nonmuscle Myosin Type IIA physiology, Thrombocytopenia etiology
- Abstract
We have generated 3 mouse lines, each with a different mutation in the nonmuscle myosin II-A gene, Myh9 (R702C, D1424N, and E1841K). Each line develops MYH9-related disease similar to that found in human patients. R702C mutant human cDNA fused with green fluorescent protein was introduced into the first coding exon of Myh9, and D1424N and E1841K mutations were introduced directly into the corresponding exons. Homozygous R702C mice die at embryonic day 10.5-11.5, whereas homozygous D1424N and E1841K mice are viable. All heterozygous and homozygous mutant mice show macrothrombocytopenia with prolonged bleeding times, a defect in clot retraction, and increased extramedullary megakaryocytes. Studies of cultured megakaryocytes and live-cell imaging of megakaryocytes in the BM show that heterozygous R702C megakaryocytes form fewer and shorter proplatelets with less branching and larger buds. The results indicate that disrupted proplatelet formation contributes to the macrothrombocytopenia in mice and most probably in humans. We also observed premature cataract formation, kidney abnormalities, including albuminuria, focal segmental glomerulosclerosis and progressive kidney disease, and mild hearing loss. Our results show that heterozygous mice with mutations in the myosin motor or filament-forming domain manifest similar hematologic, eye, and kidney phenotypes to humans with MYH9-related disease.
- Published
- 2012
- Full Text
- View/download PDF
27. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.
- Author
-
Leelahavanichkul A, Huang Y, Hu X, Zhou H, Tsuji T, Chen R, Kopp JB, Schnermann J, Yuen PS, and Star RA
- Subjects
- Animals, Antibodies administration & dosage, Antibodies therapeutic use, Apoptosis, Disease Progression, HMGB1 Protein immunology, Kidney Diseases complications, Kidney Diseases therapy, Mice, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic metabolism, Spleen pathology, Splenectomy, Treatment Outcome, HMGB1 Protein metabolism, Kidney Diseases etiology, Renal Insufficiency, Chronic pathology, Sepsis complications
- Abstract
We have shown that folate-induced kidney dysfunction and interstitial fibrosis predisposes mice to sepsis mortality. Agents that increase survival in normal septic mice were ineffective in a two-stage kidney disease model. Here we used the 5/6 nephrectomy mouse model of progressive chronic kidney disease (CKD) to study how CKD affects acute kidney injury (AKI) induced by sepsis. We induced sepsis using cecal ligation and puncture and found that the presence of CKD intensified the severity of kidney and liver injury, cytokine release, and splenic apoptosis. Accumulation of High Mobility Group Box Protein-1 (HMGB1; a late proinflammatory cytokine released from apoptotic cells), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α, interleukin (IL)-6, or IL-10 was increased in CKD or sepsis alone and to a greater extent in CKD-sepsis. Only part of the increase was explained by decreased renal clearance. Surprisingly, we found splenic apoptosis in CKD, even in the absence of sepsis. Although VEGF neutralization with soluble fms-like tyrosine kinase 1 (sFLT-1) (a soluble VEGF receptor) effectively treated sepsis, it was ineffective against CKD-sepsis. A single dose of HMGB1-neutralizing antiserum administered 6 h after sepsis alone was ineffective; however, CKD-sepsis was attenuated by anti-HMGB1. Splenectomy transiently decreased circulating HMGB1 levels, reversing the effectiveness of anti-HMGB1 treatment on CKD-sepsis. Thus, progressive CKD increases the severity of sepsis, in part, by reducing the renal clearance of several cytokines. CKD-induced splenic apoptosis and HMGB1 release could be important common mediators for both CKD and sepsis.
- Published
- 2011
- Full Text
- View/download PDF
28. Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.
- Author
-
Gordon J and Kopp JB
- Subjects
- Animals, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antihypertensive Agents therapeutic use, Calcineurin Inhibitors, Endothelins antagonists & inhibitors, Erythropoietin therapeutic use, Fatty Acids, Omega-3 administration & dosage, Feeding Behavior drug effects, Glucocorticoids therapeutic use, Humans, Kidney Diseases diet therapy, Mice, Proteinuria diet therapy, Rats, Rituximab, Transforming Growth Factors antagonists & inhibitors, Weight Loss drug effects, Weight Loss physiology, Kidney Diseases drug therapy, Proteinuria drug therapy, Renin-Angiotensin System drug effects
- Abstract
CKD is a major public health problem in the developed and the developing world. The degree of proteinuria associated with renal failure is a generally well accepted marker of disease severity. Agents with direct antiproteinuric effects are highly desirable therapeutic strategies for slowing, or even halting, progressive loss of kidney function. We review progress on therapies acting further downstream of the renin-angiotensin-aldosterone system pathway (e.g., transforming growth factor-beta antagonism, endothelin antagonism) and on those acting independent of the renin-angiotensin-aldosterone system pathway. In all, we discuss 26 therapeutic targets or compounds and 2 lifestyle changes (dietary modification and weight loss) that have been used clinically for diabetic or nondiabetic kidney disease. These therapies include endogenous molecules (estrogens, isotretinoin), biologic antagonists (monoclonal antibodies, soluble receptors), and small molecules. Where mechanistic data are available, these therapies have been shown to exert favorable effects on glomerular cell phenotype. In some cases, recent work has indicated surprising new molecular pathways for some therapies, such as direct effects on the podocyte by glucocorticoids, rituximab, and erythropoietin. It is hoped that recent advances in the basic science of kidney injury will prompt development of more effective pharmaceutical and biologic therapies for proteinuria., (Published by Elsevier Inc.)
- Published
- 2011
- Full Text
- View/download PDF
29. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
- Author
-
Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, Kopp JB, Schnermann J, Yuen PS, and Star RA
- Subjects
- Albuminuria etiology, Albuminuria physiopathology, Anemia etiology, Anemia physiopathology, Angiotensin II Type 1 Receptor Blockers pharmacology, Animals, Antihypertensive Agents pharmacology, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Chronic Disease, Desoxycorticosterone, Disease Models, Animal, Disease Progression, Fibrosis, Genetic Predisposition to Disease, Glomerulonephritis etiology, Glomerulonephritis physiopathology, Heart Diseases etiology, Heart Diseases physiopathology, Hydralazine pharmacology, Hypertension drug therapy, Hypertension genetics, Hypertension pathology, Hypertension physiopathology, Imidazoles pharmacology, Infusion Pumps, Implantable, Infusions, Subcutaneous, Kidney drug effects, Kidney pathology, Kidney Diseases genetics, Kidney Diseases pathology, Kidney Diseases physiopathology, Kidney Diseases prevention & control, Male, Mice, Mice, 129 Strain, Mice, Inbred C57BL, Sodium Chloride, Dietary, Species Specificity, Telemetry, Tetrazoles pharmacology, Time Factors, X-Ray Microtomography, Angiotensin II administration & dosage, Hypertension etiology, Kidney physiopathology, Kidney Diseases etiology, Nephrectomy
- Abstract
The remnant kidney model in C57BL/6 mice does not develop progressive chronic kidney disease (CKD). In this study we modified the model to mimic features of human CKD and to define accelerants of disease progression using three strains of mice. Following the procedure, there was a progressive increase in albuminuria, progressive loss in renal function, severe glomerulosclerosis and interstitial fibrosis, hypertension, cardiac fibrosis, and anemia by 4 weeks in CD-1 mice and by 12 weeks in 129S3 mice. In contrast, even after 16 weeks, the C57BL/6 mice with a remnant kidney had modestly increased albuminuria without increased blood pressure and without developing CKD or cardiac fibrosis. The baseline blood pressure, determined by radiotelemetry in conscious animals, correlated with CKD progression rates in each strain. Administering angiotensin II overcame the resistance of C57BL/6 mice to CKD following renal mass reduction, displaying high blood pressure and albuminuria, severe glomerulosclerosis, and loss of renal function by 4 weeks. Decreasing blood pressure with olmesartan, but not hydralazine, in CD-1 mice with a remnant kidney reduced CKD progression and cardiac fibrosis. C57BL/6 mice with a remnant kidney and DOCA-salt hypertension developed modest CKD. Each strain had similar degrees of interstitial fibrosis in three different normotensive models of renal fibrosis. Thus, reducing renal mass in CD-1 or 129S3 mice mimics many features of human CKD. Angiotensin II can convert the C57BL/6 strain from CKD resistant to susceptible in this disease model.
- Published
- 2010
- Full Text
- View/download PDF
30. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.
- Author
-
Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, and Pollak MR
- Subjects
- Animals, Apolipoprotein L1, Humans, Kidney Diseases etiology, Molecular Motor Proteins genetics, Myosin Heavy Chains genetics, Polymorphism, Single Nucleotide, Risk, Trypanosomiasis, African prevention & control, Black or African American genetics, Apolipoproteins genetics, Kidney Diseases genetics, Lipoproteins, HDL genetics
- Abstract
Mapping by admixture linkage disequilibrium (LD) detected strong association between nonmuscle myosin heavy chain 9 gene (MYH9) variants on chromosome 22 and nondiabetic nephropathy in African Americans. MYH9-related variants were posited to be the probable, but not necessarily the definitive, causal variants as a result of impressive statistical evidence of association, renal expression, and a role in autosomal dominant MYH9 disorders characterized by progressive glomerulosclerosis (Epstein and Fechtner syndromes). Dense mapping within MYH9 revealed striking LD patterns and racial variation in risk allele frequencies, suggesting population genetic factors such as selection may be operative in this region. Genovese and colleagues examined large chromosomal regions adjacent to MYH9 using genome-wide association methods and non-HapMap single nucleotide polymorphisms identified in Yoruba from the 1000 Genomes project. Statistically stronger associations were detected between two independent sequence variants in the Apolipoprotein L1 gene (APOL1) and nondiabetic nephropathy in African Americans, with odds ratios of 10.5 in idiopathic FSGS and 7.3 in hypertension-attributed ESRD. These kidney disease risk variants likely rose to high frequency in Africa because they confer resistance to trypanosomal infection and protect from African sleeping sickness. Risk variants in MYH9 and APOL1 are in strong LD, and the genetic risk that was previously attributed to MYH9 may reside, in part or in whole, in APOL1, although more complex models of risk cannot be excluded. This association likely explains racial disparities in nondiabetic nephropathy as a result of the high prevalence of risk alleles in individuals of African ancestry.
- Published
- 2010
- Full Text
- View/download PDF
31. Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa.
- Author
-
Oleksyk TK, Nelson GW, An P, Kopp JB, and Winkler CA
- Subjects
- Asian People genetics, Black People genetics, Genetics, Population, Humans, Linkage Disequilibrium genetics, Polymorphism, Single Nucleotide genetics, White People genetics, Black or African American, Alleles, Genetic Predisposition to Disease genetics, Haplotypes genetics, Kidney Diseases genetics, Molecular Motor Proteins genetics, Myosin Heavy Chains genetics
- Abstract
MYH9 was recently identified as renal susceptibility gene (OR 3-8, p < 10(-8)) for major forms of kidney disease disproportionately affecting individuals of African descent. The risk haplotype (E-1) occurs at much higher frequencies in African Americans (> or = 60%) than in European Americans (< 4%), revealing a genetic basis for a major health disparity. The population distributions of MYH9 risk alleles and the E-1 risk haplotype and the demographic and selective forces acting on the MYH9 region are not well explored. We reconstructed MYH9 haplotypes from 4 tagging single nucleotide polymorphisms (SNPs) spanning introns 12-23 using available data from HapMap Phase II, and by genotyping 938 DNAs from the Human Genome Diversity Panel (HGDP). The E-1 risk haplotype followed a cline, being most frequent within sub-Saharan African populations (range 50-80%), less frequent in populations from the Middle East (9-27%) and Europe (0-9%), and rare or absent in Asia, the Americas, and Oceania. The fixation indexes (F(ST)) for pairwise comparisons between the risk haplotypes for continental populations were calculated for MYH9 haplotypes; F(ST) ranged from 0.27-0.40 for Africa compared to other continental populations, possibly due to selection. Uniquely in Africa, the Yoruba population showed high frequency extended haplotype length around the core risk allele (C) compared to the alternative allele (T) at the same locus (rs4821481, iHs = 2.67), as well as high population differentiation (F(ST(CEU vs. YRI)) = 0.51) in HapMap Phase II data, also observable only in the Yoruba population from HGDP (F(ST) = 0.49), pointing to an instance of recent selection in the genomic region. The population-specific divergence in MYH9 risk allele frequencies among the world's populations may prove important in risk assessment and public health policies to mitigate the burden of kidney disease in vulnerable populations.
- Published
- 2010
- Full Text
- View/download PDF
32. Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism?
- Author
-
Kopp JB
- Subjects
- Humans, Kidney Diseases genetics, Kidney Glomerulus pathology, Molecular Motor Proteins genetics, Mutation, Myosin Heavy Chains genetics
- Abstract
Genetic variation in MYH9, encoding non-muscle heavy chain IIA, has been recognized for over a decade as the cause of an autosomal dominant syndrome characterized by macrothrombocytopenia, neutrophil inclusions, and glomerular pathology. More recently, genetic variation in the MYH9 region on chromosome 22 has been associated with chronic kidney disease in African-descent individuals. A better understanding of the disease mechanisms responsible for glomerular injury in autosomal dominant MYH9 syndromes will lead to fuller appreciation of the role of this gene in glomerular biology.
- Published
- 2010
- Full Text
- View/download PDF
33. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease.
- Author
-
Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, and Tufro A
- Subjects
- Age Factors, Animals, Autocrine Communication, Diabetic Nephropathies genetics, Diabetic Nephropathies pathology, Genotype, Glomerular Basement Membrane pathology, Kidney Diseases genetics, Kidney Diseases pathology, Matrix Metalloproteinase 9 metabolism, Membrane Proteins metabolism, Mice, Mice, Transgenic, Paracrine Communication, Phenotype, Phosphorylation, Podocytes pathology, Protein Binding, Proteinuria genetics, Proteinuria metabolism, Signal Transduction, Up-Regulation, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor Receptor-2 metabolism, Diabetic Nephropathies metabolism, Kidney Diseases metabolism, Podocytes metabolism, Vascular Endothelial Growth Factor A metabolism
- Abstract
We sought to examine the pathogenic role of excessive VEGF-A expression in podocytes, since it has been reported that diabetic nephropathy and other glomerular diseases are associated with increased VEGF-A expression. The induction of podocyte-specific VEGF164 overexpression in adult transgenic mice led to proteinuria, glomerulomegaly, glomerular basement membrane thickening, mesangial expansion, loss of slit diaphragms, and podocyte effacement. When doxycycline-mediated VEGF164 was stopped, these abnormalities reversed. These findings were associated with reversible downregulation of metalloproteinase 9 and nephrin expression. Using transmission electron microscopy, we established that VEGF-A receptor-2 (VEGFR2) was expressed in podocytes and glomerular endothelial cells. We also found that VEGF164 induced VEGFR2 phosphorylation in podocytes. Further, we were able to co-immunoprecipitate VEGFR2 and nephrin using whole kidney lysates, confirming interaction in vivo. This implies that autocrine and paracrine VEGF-A signaling through VEGFR2 occurs in podocytes and may mediate the glomerular phenotype caused by VEGF164 overexpression. Thus, we suggest that podocyte VEGF164 overexpression in adult mice is sufficient to induce glomerular filtration barrier structural and functional abnormalities similar to those present in murine diabetic nephropathy.
- Published
- 2010
- Full Text
- View/download PDF
34. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
- Author
-
Cho ME and Kopp JB
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Chronic Disease drug therapy, Clinical Trials as Topic, Disease Models, Animal, Disease Progression, Drug Evaluation, Fibrosis chemically induced, Humans, Pyridones adverse effects, Pyridones pharmacokinetics, Pyridones pharmacology, Fibrosis drug therapy, Kidney pathology, Kidney Diseases drug therapy, Pyridones therapeutic use
- Abstract
Importance of the Field: Many chronic diseases of various etiologies lead to fibrosis and organ dysfunction. Despite many advances in medicine in recent years, options to slow the progression of fibrotic diseases have remained limited. The recent availability of pirfenidone, an antifibrotic and anti-inflammatory investigational agent, thus offers a new hope for treating progressive fibrotic diseases., Areas Covered in This Review: This review provides concise review of the available data regarding the mechanism and pharmacokinetics of pirfenidone and preclinical and clinical data regarding efficacy and safety in fibrotic diseases of the kidney. It also reviews results of clinical trials involving pirfenidone in other fibrotic diseases., What the Reader Will Gain: The review will provide in-depth review of pirfenidone with a renal focus., Take Home Message: Because many of the available clinical trials have been small and/or uncontrolled, conclusive evidence regarding efficacy and safety of pirfenidone is lacking, particularly in patients with renal or hepatic dysfunction. Larger studies are needed to better understand long-term efficacy and safety of this medication in various patient populations.
- Published
- 2010
- Full Text
- View/download PDF
35. Renal gene and protein expression signatures for prediction of kidney disease progression.
- Author
-
Ju W, Eichinger F, Bitzer M, Oh J, McWeeney S, Berthier CC, Shedden K, Cohen CD, Henger A, Krick S, Kopp JB, Stoeckert CJ Jr, Dikman S, Schröppel B, Thomas DB, Schlondorff D, Kretzler M, and Böttinger EP
- Subjects
- Animals, Cluster Analysis, Disease Progression, Gene Expression, Humans, Immunohistochemistry, Kidney Diseases metabolism, Mice, Mice, Transgenic, Oligonucleotide Array Sequence Analysis, RNA, Messenger analysis, Reverse Transcriptase Polymerase Chain Reaction, Risk Factors, Transcription, Genetic, Transforming Growth Factor beta1 genetics, Gene Expression Profiling, Kidney Diseases genetics, Kidney Diseases pathology
- Abstract
Although chronic kidney disease (CKD) is common, only a fraction of CKD patients progress to end-stage renal disease. Molecular predictors to stratify CKD populations according to their risk of progression remain undiscovered. Here we applied transcriptional profiling of kidneys from transforming growth factor-beta1 transgenic (Tg) mice, characterized by heterogeneity of kidney disease progression, to identify 43 genes that discriminate kidneys by severity of glomerular apoptosis before the onset of tubulointerstitial fibrosis in 2-week-old animals. Among the genes examined, 19 showed significant correlation between mRNA expression in uninephrectomized left kidneys at 2 weeks of age and renal disease severity in right kidneys of Tg mice at 4 weeks of age. Gene expression profiles of human orthologs of the 43 genes in kidney biopsies were highly significantly related (R(2) = 0.53; P < 0.001) to the estimated glomerular filtration rates in patients with CKD stages I to V, and discriminated groups of CKD stages I/II and III/IV/V with positive and negative predictive values of 0.8 and 0.83, respectively. Protein expression patterns for selected genes were successfully validated by immunohistochemistry in kidneys of Tg mice and kidney biopsies of patients with IgA nephropathy and CKD stages I to V, respectively. In conclusion, we developed novel mRNA and protein expression signatures that predict progressive renal fibrosis in mice and may be useful molecular predictors of CKD progression in humans.
- Published
- 2009
- Full Text
- View/download PDF
36. Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.
- Author
-
Barisoni L, Schnaper HW, and Kopp JB
- Subjects
- Apoptosis drug effects, Cell Differentiation drug effects, Cell Proliferation drug effects, Humans, Kidney Diseases diagnosis, Mutation genetics, Podocytes drug effects, Kidney Diseases genetics, Kidney Diseases pathology, Podocytes pathology
- Abstract
Context: Etiologic factors and pathways leading to altered podocyte phenotype are clearly numerous and involve the activity of different cellular function., Objective: To focus on recent discoveries in podocyte biology and genetics and their relevance to these human glomerular diseases, named podocytopathies., Data Sources: Genetic mutations in genes encoding for proteins in the nucleus, slit diaphragm, podocyte cytoplasm, and cell membrane are responsible for podocyte phenotype and functional abnormalities. Podocyte injury may also derive from secondary stimuli, such as mechanical stress, infections, or use of certain medications. Podocytes can respond to injury in a limited number of ways, which include (1) effacement, (2) apoptosis, (3) arrest of development, and (4) dedifferentiation. Each of these pathways results in a specific glomerular morphology: minimal change nephropathy, focal segmental glomerulosclerosis, diffuse mesangial sclerosis, and collapsing glomerulopathy., Conclusions: Based on current knowledge of podocyte biology, we organized etiologic factors and morphologic features in a taxonomy of podocytopathies, which provides a novel approach to the classification of these diseases. Current and experimental therapeutic approaches are also discussed.
- Published
- 2009
- Full Text
- View/download PDF
37. Viruses and kidney disease: beyond HIV.
- Author
-
Waldman M, Marshall V, Whitby D, and Kopp JB
- Subjects
- Diagnosis, Differential, HIV genetics, Humans, Kidney Diseases diagnosis, Kidney Diseases epidemiology, Kidney Diseases etiology, RNA, Viral analysis, Virus Diseases complications, Virus Diseases diagnosis, Virus Diseases virology, Viruses genetics
- Abstract
Summary: Human immunodeficiency virus (HIV)-infected patients may acquire new viral co-infections; they also may experience the reactivation or worsening of existing viral infections, including active, smoldering, or latent infections. HIV-infected patients may be predisposed to these viral infections owing to immunodeficiency or risk factors common to HIV and other viruses. A number of these affect the kidney, either by direct infection or by deposition of immune complexes. In this review we discuss the renal manifestations and treatment of hepatitis C virus, BK virus, adenovirus, cytomegalovirus, and parvovirus B19 in patients with HIV disease. We also discuss an approach to the identification of new viral renal pathogens, using a viral gene chip to identify viral DNA or RNA.
- Published
- 2008
- Full Text
- View/download PDF
38. Urinary exosomal transcription factors, a new class of biomarkers for renal disease.
- Author
-
Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, and Star RA
- Subjects
- Activating Transcription Factor 3 urine, Acute Kidney Injury chemically induced, Acute Kidney Injury urine, Adult, Aged, Animals, Biomarkers urine, Case-Control Studies, Cisplatin toxicity, Gene Products, vpr genetics, Glomerulosclerosis, Focal Segmental urine, Humans, Intracellular Signaling Peptides and Proteins genetics, Kidney injuries, Male, Membrane Proteins genetics, Mice, Mice, Transgenic, Middle Aged, Podocytes drug effects, Podocytes pathology, Podocytes physiology, Rats, Rats, Sprague-Dawley, Reperfusion Injury urine, WT1 Proteins urine, Kidney Diseases urine, Transcription Factors urine
- Abstract
Urinary exosomes are excreted from all nephron segments and constitute a rich source of intracellular kidney injury biomarkers. To study whether they contain transcription factors, we collected urine from two acute kidney injury models (cisplatin or ischemia-reperfusion), two podocyte injury models (puromycin-treated rats or podocin-Vpr transgenic mice) and from patients with focal segmental glomerulosclerosis, acute kidney injury and matched controls. Exosomes were isolated by differential centrifugation and found to contain activating transcription factor 3 (ATF3) and Wilms Tumor 1 (WT-1) proteins detected by Western blot. These factors were found in the concentrated exosomal fraction, but not in whole urine. ATF3 was continuously present in urine exosomes of the rat models following acute injury at times earlier than the increase in serum creatinine. ATF3 was found in exosomes isolated from patients with acute kidney injury but not from patients with chronic kidney disease or controls. Urinary WT-1 was present in animal models before significant glomerular sclerosis and in 9/10 patients with focal segmental glomerulosclerosis but not in 8 controls. Our findings suggest that transcription factor ATF3 may provide a novel renal tubular cell biomarker for acute kidney injury while WT-1 may detect early podocyte injury. Measurement of urinary exosomal transcription factors may offer insight into cellular regulatory pathways.
- Published
- 2008
- Full Text
- View/download PDF
39. Kidney patient care in disasters: lessons from the hurricanes and earthquake of 2005.
- Author
-
Kopp JB, Ball LK, Cohen A, Kenney RJ, Lempert KD, Miller PE, Muntner P, Qureshi N, and Yelton SA
- Subjects
- Acute Kidney Injury therapy, Humans, Louisiana, Pakistan, Disasters, Emergency Medical Services, Kidney Diseases therapy
- Abstract
The active 2005 hurricane season alerted Americans to the pressing need for a more effective response to mass casualty incidents. The kidney patient community was particularly affected. Ninety-four dialysis facilities in the Gulf Coast states closed for at least 1 wk in the aftermath of Hurricane Katrina, and additional units were affected by evacuation of dialysis patients. Dialysis units along the Gulf Coast were also affected by Hurricanes Rita and Wilma. Existing emergency response plans were inadequate in providing continuity of care for kidney patients. The Kashmir, South Asia, earthquake of October 2005 killed 97,000 individuals. Building collapse was associated with widespread crush injury, and many patients required temporary hemodialysis. Several regions of the United States have the potential for catastrophic earthquakes. The Kidney Community Emergency Response Coalition has recently issued recommendations for patients, dialysis facilities, and providers, with a goal to improve care of kidney patients in future domestic disasters. With suitable planning, the nephrology community can do much to ensure the continuity of medical care for kidney patients in the face of a wide range of possible natural and human-made disasters.
- Published
- 2007
- Full Text
- View/download PDF
40. Parvovirus B19 and the kidney.
- Author
-
Waldman M and Kopp JB
- Subjects
- Humans, Kidney Diseases diagnosis, Kidney Diseases epidemiology, Kidney Diseases therapy, Parvoviridae Infections diagnosis, Parvoviridae Infections epidemiology, Parvoviridae Infections therapy, Kidney virology, Kidney Diseases virology, Parvoviridae Infections virology, Parvovirus B19, Human
- Abstract
Infection with parvovirus B19 causes several clinical syndromes (fifth disease, transient aplastic crisis, pure red cell aplasia, and hydrops fetalis) and may contribute to other illnesses. B19 has been linked to renal disease in three settings: As a cause of acute glomerulopathy and as a cause of anemia in ESRD and kidney transplantation. Case reports implicate parvovirus in the pathogenesis of proliferative glomerulonephritis and collapsing glomerulopathy, but a causal relationship has not been established. A proposed role for B19 infection is based on the temporal association of renal findings with viral infection, positive serology, and identification of the viral genome in the glomerulus. Mechanisms may include cytopathic effects on glomerular epithelial cells and/or endothelial cells and glomerular deposition of immune complexes. Patients who require dialysis may have increased susceptibility to acute and chronic anemia after parvoviral infection. Factors that predispose this population to complications of B19 infection include impaired immune response, deficient erythropoietin production, and possibly decreased erythrocyte survival. The clinical burden of parvovirus B19 infection in renal transplant recipients may be underestimated; these individuals may develop persistent viremia as a result of a dysfunctional immune response. Chronic anemia and pure red blood cell aplasia are the most common complications of parvovirus infection in this population; the diagnosis should be considered in transplant recipients with unexplained anemia or pancytopenia. Allograft rejection and dysfunction have been reported in association with infection, but a cause-effect relationship has not been proved. Further investigation of the relationship between B19 and kidney disease is warranted.
- Published
- 2007
- Full Text
- View/download PDF
41. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases.
- Author
-
Barisoni L, Schnaper HW, and Kopp JB
- Subjects
- Humans, Kidney Diseases complications, Kidney Diseases etiology, Proteinuria etiology, Kidney Diseases classification, Kidney Diseases pathology, Kidney Glomerulus, Podocytes pathology
- Abstract
A spectrum of proteinuric glomerular diseases results from podocyte abnormalities. The understanding of these podocytopathies has greatly expanded in recent years, particularly with the discovery of more than a dozen genetic mutations that are associated with loss of podocyte functional integrity. It is apparent that classification of the podocytopathies on the basis of morphology alone is inadequate to capture fully the complexity of these disorders. Herein is proposed a taxonomy for the podocytopathies that classifies along two dimensions: Histopathology, including podocyte phenotype and glomerular morphology (minimal-change nephropathy, focal segmental glomerulosclerosis, diffuse mesangial sclerosis, and collapsing glomerulopathy), and etiology (idiopathic, genetic, and reactive forms). A more complete understanding of the similarities and differences among podocyte diseases will help the renal pathologist and the nephrologist communicate more effectively about the diagnosis; this in turn will help the nephrologist provide more accurate prognostic information and select the optimal therapy for these often problematic diseases. It is proposed that final diagnosis of the podocytopathies should result from close collaboration between renal pathologists and nephrologists and should whenever possible include three elements: Morphologic entity, etiologic form, and specific pathogenic mechanism or association.
- Published
- 2007
- Full Text
- View/download PDF
42. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity.
- Author
-
Cho ME, Hurley JK, and Kopp JB
- Subjects
- Adult, Female, Glomerular Filtration Rate physiology, Glomerulosclerosis, Focal Segmental complications, Glomerulosclerosis, Focal Segmental physiopathology, Humans, In Vitro Techniques, Kidney Diseases complications, Kidney Diseases physiopathology, Male, Middle Aged, Proteinuria chemically induced, Proteinuria complications, Proteinuria physiopathology, Glomerulosclerosis, Focal Segmental drug therapy, Kidney Diseases chemically induced, Sirolimus adverse effects
- Abstract
To evaluate the safety and efficacy of sirolimus in treating patients with focal segmental glomerulosclerosis (FSGS), we performed a phase 2, open-label clinical trial. Inclusion criteria were adults and children 13 years and older with biopsy-proven idiopathic FSGS, proteinuria with protein of 3.5 g/d or greater while on angiotensin antagonist therapy, glomerular filtration rate (GFR) of 30 mL/min/1.73 m(2) or greater (>or=0.50 mL/s), and failure to achieve sustained remission with at least 1 immunosuppressive agent. Eligible patients received sirolimus doses adjusted to achieve trough levels of 5 to 15 ng/mL during the first 4 months and 10 to 20 ng/mL for the subsequent 8 months. The primary outcome was decrease in proteinuria, expressed as complete remission (protein < 0.3 g/d) or partial remission (protein >or= 50% decrease and <3.5 g/d). Six adult patients with FSGS were enrolled in the study; they had median disease duration of 4.0 years, mean age of 39 +/- 11 years, mean baseline Modification of Diet in Renal Disease-estimated GFR of 52 +/- 15 mL/min/1.73 m(2) (0.87 +/- 0.25 mL/s), and median baseline proteinuria with protein of 6.6 g/d (interquartile range, 4.2 to 9.4). Five patients had received cyclosporine. No patient experienced a complete or partial remission. Sirolimus therapy was stopped prematurely in 5 patients for the following reasons: (1) precipitous decrease in GFR in 4 patients after 7 to 9 months of therapy with a greater than 2-fold increase in proteinuria in 3 patients and (2) hypertriglyceridemia with triglyceride levels greater than 1,600 mg/dL (>18 mmol/L) at 5 months in 1 patient. Because of a rapid decrease in GFR with worsening proteinuria, the protocol was closed to further recruitment. We conclude that sirolimus may be associated with nephrotoxicity in some patients with FSGS, particularly those with prolonged disease duration and prior cyclosporine therapy.
- Published
- 2007
- Full Text
- View/download PDF
43. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations.
- Author
-
Kimmel PL, Barisoni L, and Kopp JB
- Subjects
- Animals, Genetic Predisposition to Disease, HIV Infections genetics, Humans, Kidney Diseases diagnosis, HIV Infections complications, Kidney Diseases etiology, Kidney Diseases therapy
- Abstract
HIV infection is associated with several renal syndromes, including acute renal failure. Chronic renal failure directly linked to HIV infection includes thrombotic microangiopathic renal diseases, immune-mediated glomerulonephritides, and HIV-associated nephropathy. A renal biopsy may be necessary for diagnosis. The development of HIV-associated nephropathy has been definitively linked to renal cellular infection, but the disease affects only a minority of patients, typically men of African descent. Therefore, factors determining disease expression in infected patients must now be emphasized. The pathogenic mechanisms involved in HIV-associated renal disease remain obscure. Genetic factors, as well as renal cellular responses, mediated by HIV proteins (including an immune-activated microenvironment) capable of presenting antigen in susceptible hosts probably explain most cases. HIV-associated nephropathy has a characteristic pathologic phenotype, including glomerular, tubular, and interstitial changes, and ultrastructural findings. Infection of the glomerular epithelial cell, or podocyte, and consequent structural and biochemical changes may be pivotal in pathogenesis. The HIV-1 transgenic mouse is an important model for understanding disease pathogenesis, particularly the role of HIV proteins in mediating renal tissue injury. Rigorously controlled randomized trials have not evaluated treatment, but corticosteroids and angiotensin-converting enzyme inhibitors have been used. Highly active antiretroviral therapy seems to have decreased the incidence of end-stage renal disease related to HIV infection and, in case reports, to have improved renal functional and pathologic outcomes of HIV-associated nephropathy. Outcomes in patients undergoing hemodialysis and peritoneal dialysis have improved, and current research focuses on renal transplantation for treatment of HIV-infected patients.
- Published
- 2003
44. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility.
- Author
-
Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, Unanue ER, and Shaw AS
- Subjects
- Adaptor Proteins, Signal Transducing, Animals, Antigen-Antibody Complex, Basement Membrane immunology, Basement Membrane metabolism, Basement Membrane pathology, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Endocytosis, Epithelial Cells pathology, Epithelial Cells physiology, Exons, Ferritins metabolism, Genetic Variation, Glomerular Mesangium immunology, Glomerular Mesangium pathology, Glomerulosclerosis, Focal Segmental metabolism, Glomerulosclerosis, Focal Segmental pathology, Heterozygote, Humans, Immunoglobulins analysis, Kidney Diseases metabolism, Kidney Diseases pathology, Mice, Mice, Knockout, Mutation, Polymerase Chain Reaction, Polymorphism, Genetic, Proteinuria etiology, RNA Splicing, Genetic Predisposition to Disease, Glomerulosclerosis, Focal Segmental genetics, Kidney Diseases genetics, Kidney Glomerulus immunology, Kidney Glomerulus metabolism, Kidney Glomerulus pathology, Proteins genetics, Proteins physiology
- Abstract
Loss of CD2-associated protein (CD2AP), a component of the filtration complex in the kidney, causes death in mice at 6 weeks of age. Mice with CD2AP haploinsufficiency developed glomerular changes at 9 months of age and had increased susceptibility to glomerular injury by nephrotoxic antibodies or immune complexes. Electron microscopic analysis of podocytes revealed defects in the formation of multivesicular bodies, suggesting an impairment of the intracellular degradation pathway. Two human patients with focal segmental glomerulosclerosis had a mutation predicted to ablate expression of one CD2AP allele, implicating CD2AP as a determinant of human susceptibility to glomerular disease.
- Published
- 2003
- Full Text
- View/download PDF
45. Renal fibrosis.
- Author
-
Schnaper HW and Kopp JB
- Subjects
- Animals, Fibrosis, Humans, Kidney Diseases etiology, Kidney Diseases genetics, Kidney Diseases physiopathology, Kidney pathology, Kidney Diseases pathology
- Abstract
Renal fibrosis causes significant morbidity and mortality as the primary acquired lesion leading to the need for dialysis or kidney transplantation. Fibrosis can occur in either the filtering or reabsorptive component of the nephron, the functional unit of the kidney. Experimental models have identified a number of factors that contribute to renal scarring, particularly derangements of physiology involved in the autoregulation of glomerular filtration. This in turn leads to replacement of normal structures with accumulated extracellular matrix (ECM). A spectrum of changes in the physiology of individual cells leads to the production of numerous peptide and non-peptide fibrogens that stimulate alterations in the balance between ECM synthesis and degradation to favor scarring. Other proteins and small molecules may have anti-fibrotic effects. Manipulation of these opposing systems holds the promise of effective treatments for chronic progressive kidney disease.
- Published
- 2003
- Full Text
- View/download PDF
46. BK virus and SV40 co-infection in polyomavirus nephropathy.
- Author
-
Li RM, Mannon RB, Kleiner D, Tsokos M, Bynum M, Kirk AD, and Kopp JB
- Subjects
- Adult, Cells, Cultured, DNA, Viral metabolism, Female, Humans, JC Virus genetics, JC Virus physiology, Kidney Diseases metabolism, Kidney Transplantation, Male, Middle Aged, Polyomavirus Infections metabolism, Postoperative Complications, Transplantation, Homologous, Tumor Virus Infections metabolism, Virus Replication, BK Virus genetics, BK Virus physiology, Kidney Diseases virology, Polyomavirus Infections complications, Simian virus 40 genetics, Simian virus 40 physiology, Tumor Virus Infections complications
- Abstract
Background: Polyomavirus (PV) nephropathy has been attributed to reactivation of BK virus (BKV) or more rarely JC virus (JCV). The simian virus (SV) 40 is PV that was likely introduced into the human population through contaminated vaccines. The purpose of this study was to identify and characterize the PV that is associated with PV nephropathy., Methods: The clinical diagnosis of PV nephropathy (PVN) was made in patients with acute deterioration in renal function whose renal biopsies showed typical viral cytopathic changes in tubular epithelial cells and staining for PV T antigen. Polymerase chain reaction (PCR) amplification of DNA from peripheral blood mononuclear cells (PBMC), urinary cells, and renal biopsy tissue was performed using specific primers for the transcription control regions of BKV, JCV, and SV40, respectively., Results: Six cases of PV nephropathy were identified in 91 renal transplant recipients (7%). Immunosuppressive therapy was modified in all patients. Renal function stabilized or improved in four patients and deteriorated in two patients, and one patient has lost his allograft, after follow-up from 2 to 25 months. PCR detection demonstrated BKV genome in three of five PBMC samples, six of six urinary cell samples, and two of four renal biopsies. SV40 genome was detected in two of five PBMC samples, one of six urinary cell samples, and two of four renal biopsies. Infectious SV40 and BKV was demonstrated in CV-1 co-cultures using urine from one patient. JCV was not detected in any PVN sample. Co-infection with BKV and SV40 was found in two PVN patients. Urine samples obtained 12 months after transplant from 26 transplant recipients without PVN on simultaneous protocol renal biopsy were analyzed by PCR; BKV genome was demonstrated in 5 of 25 samples, JCV genome was demonstrated in 3 of 25 samples, and SV40 genome was demonstrated in 0 of 25 samples., Conclusion: The authors report molecular evidence that co-infection with BKV and SV40 occurs in renal transplant patients with PVN, suggesting that SV40 may contribute to PVN after renal transplant.
- Published
- 2002
- Full Text
- View/download PDF
47. Natural history and treatment of renal involvement in Fabry disease.
- Author
-
Branton M, Schiffmann R, and Kopp JB
- Subjects
- Fabry Disease enzymology, Fabry Disease genetics, Humans, Kidney Diseases diagnosis, Mutation, Trihexosylceramides metabolism, alpha-Galactosidase metabolism, alpha-Galactosidase therapeutic use, Fabry Disease complications, Kidney Diseases therapy
- Published
- 2002
48. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.
- Author
-
Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, and Kopp JB
- Subjects
- Adolescent, Adult, Age of Onset, Child, Child, Preschool, Disease Progression, Fabry Disease epidemiology, Fabry Disease genetics, Fabry Disease surgery, Humans, Hypertension, Renal epidemiology, Hypertension, Renal etiology, Infant, Infant, Newborn, Kidney pathology, Kidney Diseases epidemiology, Kidney Diseases genetics, Kidney Diseases surgery, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic etiology, Kidney Transplantation, Male, Middle Aged, Mutation, Proteinuria epidemiology, Proteinuria etiology, United States epidemiology, Fabry Disease physiopathology, Kidney Diseases physiopathology, alpha-Galactosidase genetics, alpha-Galactosidase metabolism
- Published
- 2002
- Full Text
- View/download PDF
49. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
- Author
-
Genovese, Giulio, Friedman, David J., Ross, Michael D., Lecordier, Laurence, Uzureau, Pierrick, Freedman, Barry I., Bowden, Donald W., Langefeld, Carl D., Oleksyk, Taras K., Knob, Andrea L. Uscinski, Bernhardy, Andrea J., Hicks, Pamela J., Nelson, George W., Vanhollebeke, Benoit, Winkler, Cheryl A., Kopp, Jeffrey B., Pays, Etienne, and Pollak, Martin R.
- Published
- 2010
50. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.
- Author
-
Young, Bessie A., Blacksher, Erika, Cavanaugh, Kerri L., Freedman, Barry I., Fullerton, Stephanie M., Kopp, Jeffrey B., Umeukeje, Ebele M., West, Kathleen M., Wilson, James G., Burke, Wylie, Young, Bessie A, Cavanaugh, Kerri L, Freedman, Barry I, Fullerton, Stephanie M, Kopp, Jeffrey B, Umeukeje, Ebele M, West, Kathleen M, Wilson, James G, and APOL1 Stakeholders Project
- Subjects
AFRICAN Americans ,KIDNEY transplantation ,CHRONIC kidney failure ,KIDNEY diseases ,COMMUNITIES - Abstract
Background: Apolipoprotein A1 (APOL1) gene variants occurring in people of West African descent contribute to the greater burden of kidney disease among African Americans. These variants are associated with increased risk of nondiabetic nephropathy, more rapid progression of chronic kidney disease, and shorter survival of donor kidneys after transplantation. However, only a minority of people with APOL1-associated risk develops kidney disease and specific clinical measures to address APOL1-associated risk are lacking. Given these uncertainties, we sought to engage members of the African American public in discussions with other stakeholders about the appropriate use of APOL1 testing.Methods: Formative interviews with community members, researchers, and clinicians in Seattle WA, Nashville TN, and Jackson MS, provided baseline information about views toward APOL1 testing and informed the design of 3 community-based deliberations among African Americans. A national meeting held in March 2018 included 13 community members, 7 scientific advisors and 26 additional researchers, clinicians, bioethicists, patient advocates, and representatives from professional organizations and federal funding agencies. Using small break-out and plenary discussion, the group agreed on recommendations based on current knowledge about APOL1-associated risk.Results: Meeting outcomes included recommendations to develop educational materials about APOL1 for community members and clinicians; to offer APOL1 research results to participants; and on the use of APOL1testing in kidney transplant programs. The group recommended against the routine offer of APOL1 testing in clinical care. Areas of disagreement included whether kidney transplant programs should require APOL1 testing of prospective living donors or bar individuals with APOL1 risk from donating kidneys and whether testing should be available on request in routine clinical care.Conclusion: We recommend continued discussion among stakeholders and concerted efforts to ensure active and informed participation of members of the affected community to guide research on APOL1 and kidney disease. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.